{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:31:24Z","timestamp":1779309084210,"version":"3.51.4"},"reference-count":34,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2017.00062","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T08:21:10Z","timestamp":1491294070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase I Trial of Triapine\u2013Cisplatin\u2013Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers"],"prefix":"10.3389","volume":"7","author":[{"given":"Charles A.","family":"Kunos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Della","family":"Makower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kaubisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"issue":"9","key":"B1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/IGC.0b013e318270577f","article-title":"Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers","volume":"22","author":"Kunos","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"B2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/IGC.0b013e31828b4eb5","article-title":"Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis","volume":"23","author":"Kunos","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"B3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"B4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"B5","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1200\/JCO.1999.17.9.2676","article-title":"Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"17","author":"Rose","year":"1999","journal-title":"J Clin Oncol"},{"issue":"16","key":"B6","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.2004.12.006","article-title":"Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Morris","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2004.05.018","article-title":"Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"94","author":"Muggia","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"2","key":"B8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ygyno.2011.01.030","article-title":"Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study","volume":"121","author":"Farley","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"25","key":"B9","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1200\/JCO.2013.54.7448","article-title":"Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group","volume":"32","author":"Miller","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"B10","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1074\/jbc.M512894200","article-title":"Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells","volume":"281","author":"Hakansson","year":"2006","journal-title":"J Biol Chem"},{"issue":"42","key":"B11","doi-asserted-by":"publisher","first-page":"33021","DOI":"10.1074\/jbc.M005337200","article-title":"Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase","volume":"275","author":"Reichard","year":"2000","journal-title":"J Biol Chem"},{"issue":"2","key":"B12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/15257770.2011.644370","article-title":"On model ensemble analyses of nonmonotonic data","volume":"31","author":"Radivoyevitch","year":"2012","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"6","key":"B13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1667\/RR1858.1","article-title":"Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein","volume":"172","author":"Kunos","year":"2009","journal-title":"Radiat Res"},{"issue":"5","key":"B14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1667\/RR2273.1","article-title":"Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers","volume":"174","author":"Kunos","year":"2010","journal-title":"Radiat Res"},{"issue":"4","key":"B15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1667\/RR2556.1","article-title":"Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers","volume":"176","author":"Kunos","year":"2011","journal-title":"Radiat Res"},{"issue":"9","key":"B16","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1158\/1078-0432.CCR-05-2860","article-title":"In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone)","volume":"12","author":"Barker","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0065-2571(98)00017-X","article-title":"Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity","volume":"39","author":"Finch","year":"1999","journal-title":"Adv Enzyme Regul"},{"issue":"8","key":"B18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0006-2952(99)00419-0","article-title":"Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity","volume":"59","author":"Finch","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"B19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0092-8674(03)00075-8","article-title":"Survival of DNA damage in yeast directly depends on increased dNTP levels allowed by relaxed feedback inhibition of ribonucleotide reductase","volume":"112","author":"Chabes","year":"2003","journal-title":"Cell"},{"issue":"3","key":"B20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00280-002-0480-0","article-title":"Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule","volume":"50","author":"Feun","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"B21","first-page":"4092","article-title":"Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors","volume":"9","author":"Murren","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"9","key":"B22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.2004.07.158","article-title":"Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion","volume":"22","author":"Wadler","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"B23","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"B24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"Kunos","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fonc.2014.00184","article-title":"Long-term disease control with triapine-based radiochemotherapy for patients with stage IB2-IIIB cervical cancer","volume":"4","author":"Kunos","year":"2014","journal-title":"Front Oncol"},{"issue":"3","key":"B26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"B27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00775-013-1070-9","article-title":"Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia","volume":"19","author":"Basha","year":"2014","journal-title":"J Biol Inorg Chem"},{"issue":"3","key":"B28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.1999.17.3.761","article-title":"Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix","volume":"17","author":"Papadimitriou","year":"1999","journal-title":"J Clin Oncol"},{"key":"B29","first-page":"160a","article-title":"A phase I study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) in combination with cisplatin (CDDP)","volume":"22","author":"Murren","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"4","key":"B30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00280-004-0821-2","article-title":"A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer","volume":"54","author":"Yen","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"B31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.leukres.2005.12.013","article-title":"Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome","volume":"30","author":"Yee","year":"2006","journal-title":"Leuk Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1479-5876-10-79","article-title":"Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study","volume":"10","author":"Kunos","year":"2012","journal-title":"J Transl Med"},{"issue":"3","key":"B33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4161\/cc.2.3.354","article-title":"DNA building blocks at the foundation of better survival","volume":"2","author":"Chabes","year":"2003","journal-title":"Cell Cycle"},{"issue":"7","key":"B34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/bjc.2016.54","article-title":"Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair","volume":"114","author":"Ratner","year":"2016","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T08:21:11Z","timestamp":1491294071000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":34,"URL":"https:\/\/doi.org\/10.3389\/fonc.2017.00062","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]}}}